Theriva Biologics, Inc.TOVXNYSE
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +66.40% | +96.54% | +305.66% | +771.35% | +753.01% |
| Weighted Average Shares Diluted Growth | +66.40% | +96.54% | +305.66% | +770.52% | +753.01% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +27.11% | +71.29% | -11.11% | -2.64% | -8.89% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -34.83% | -35.98% | -34.00% | -15.48% | -23.12% |
| Book Value per Share Growth | -66.26% | -75.56% | -88.80% | -95.59% | -96.79% |
| Debt Growth | -21.74% | -27.34% | +41.48% | +57.98% | +58.83% |
| R&D Expense Growth | -31.75% | -31.22% | -14.19% | -33.86% | -6.69% |
| SG&A Expenses Growth | +27.04% | -9.80% | -24.60% | +662.03% | -17.94% |